IL309309A - Formulations of factor VIII chimeric proteins and uses thereof - Google Patents
Formulations of factor VIII chimeric proteins and uses thereofInfo
- Publication number
- IL309309A IL309309A IL309309A IL30930923A IL309309A IL 309309 A IL309309 A IL 309309A IL 309309 A IL309309 A IL 309309A IL 30930923 A IL30930923 A IL 30930923A IL 309309 A IL309309 A IL 309309A
- Authority
- IL
- Israel
- Prior art keywords
- formulations
- factor viii
- chimeric proteins
- viii chimeric
- proteins
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214246P | 2021-06-23 | 2021-06-23 | |
| US202163214245P | 2021-06-23 | 2021-06-23 | |
| US202163214752P | 2021-06-24 | 2021-06-24 | |
| US202163231909P | 2021-08-11 | 2021-08-11 | |
| PCT/US2022/034747 WO2022271962A1 (en) | 2021-06-23 | 2022-06-23 | Formulations of factor viii chimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309309A true IL309309A (en) | 2024-02-01 |
Family
ID=82656587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309309A IL309309A (en) | 2021-06-23 | 2022-06-23 | Formulations of factor VIII chimeric proteins and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240287158A1 (enExample) |
| EP (1) | EP4358938A1 (enExample) |
| JP (1) | JP2024522855A (enExample) |
| KR (1) | KR20240024949A (enExample) |
| AU (1) | AU2022298798A1 (enExample) |
| BR (1) | BR112023026782A2 (enExample) |
| CA (1) | CA3220564A1 (enExample) |
| CO (1) | CO2023017358A2 (enExample) |
| IL (1) | IL309309A (enExample) |
| MX (1) | MX2023015238A (enExample) |
| TW (1) | TW202317178A (enExample) |
| WO (1) | WO2022271962A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| EP4489771A2 (en) * | 2022-03-08 | 2025-01-15 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE198277T1 (de) * | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| EP2385825B1 (en) * | 2008-11-07 | 2018-10-10 | University of Connecticut | Factor viii formulations |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| AU2020298233A1 (en) * | 2019-06-19 | 2022-01-20 | Bioverativ Therapeutics Inc. | Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density |
| WO2021032646A1 (en) * | 2019-08-16 | 2021-02-25 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
| EP4489771A2 (en) * | 2022-03-08 | 2025-01-15 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
-
2022
- 2022-06-23 TW TW111123492A patent/TW202317178A/zh unknown
- 2022-06-23 BR BR112023026782A patent/BR112023026782A2/pt unknown
- 2022-06-23 EP EP22744880.0A patent/EP4358938A1/en active Pending
- 2022-06-23 CA CA3220564A patent/CA3220564A1/en active Pending
- 2022-06-23 KR KR1020247002191A patent/KR20240024949A/ko active Pending
- 2022-06-23 WO PCT/US2022/034747 patent/WO2022271962A1/en not_active Ceased
- 2022-06-23 JP JP2023579138A patent/JP2024522855A/ja active Pending
- 2022-06-23 IL IL309309A patent/IL309309A/en unknown
- 2022-06-23 MX MX2023015238A patent/MX2023015238A/es unknown
- 2022-06-23 AU AU2022298798A patent/AU2022298798A1/en active Pending
- 2022-06-23 US US18/572,006 patent/US20240287158A1/en active Pending
-
2023
- 2023-12-14 CO CONC2023/0017358A patent/CO2023017358A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240287158A1 (en) | 2024-08-29 |
| CA3220564A1 (en) | 2022-12-29 |
| TW202317178A (zh) | 2023-05-01 |
| CO2023017358A2 (es) | 2024-01-15 |
| EP4358938A1 (en) | 2024-05-01 |
| JP2024522855A (ja) | 2024-06-21 |
| KR20240024949A (ko) | 2024-02-26 |
| BR112023026782A2 (pt) | 2024-03-12 |
| AU2022298798A1 (en) | 2024-02-08 |
| MX2023015238A (es) | 2024-03-08 |
| WO2022271962A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2600834B (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| GB2617474B (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| GB2602612B (en) | Compositions of protein complexes and methods of use thereof | |
| IL280149A (en) | Methods and preparations of OTC constructs and vectors | |
| IL276823A (en) | Casein formulations and their use | |
| IL280147A (en) | Methods and preparations of MMA constructs and vectors | |
| IL282205A (en) | Preparation of stabilized polypeptide with a bisulfide bond and methods of use | |
| IL319851A (en) | LRRC-15 binding protein structures and uses thereof | |
| IL281377A (en) | Nanoparticulate preparations and methods of use for the C-terminal peptides of alpha connexin | |
| IL299847A (en) | Diester cosmetic formulations and uses thereof | |
| AU2022298798A1 (en) | Formulations of factor viii chimeric proteins and uses thereof | |
| EP3998282A4 (en) | NEW FUSION PROTEIN AND ITS USE | |
| IL318328A (en) | Compositions comprising multi-agonist peptides and methods for making and using them | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| GB202314244D0 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| IL304118A (en) | Phrase structures and their uses | |
| IL311969A (en) | Formulations of factor VIII chimeric proteins and uses thereof | |
| GB202504443D0 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| CA3260004A1 (en) | Methods and compositions for improved expression of recombinant proteins | |
| IL312802A (en) | Compositions of protein complexes and methods of using them | |
| IL284208A (en) | Antibody formulations that bind human cd137 and their uses | |
| IL289219A (en) | Composition and methods of stabilizing liquid protein formulations | |
| HK40114756A (en) | Formulations of factor viii chimeric proteins and uses thereof | |
| HK40110057A (en) | Formulations of factor viii chimeric proteins and uses thereof | |
| IL311037A (en) | Lactoferrin preparations and methods of use |